Genentech presents Phase III one-year data for vamikibart in uveitic macular edema
FROM THE WIRE · FINANCE.YAHOO.COM
In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks UME is the leading cause of moderate and severe vision loss in patients with uveitis, posing a significant risk of…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive trial data support the drug's approval potential, with FDA decision expected by July 2027.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in UME patients at 52 weeks.
- 02UME is the leading cause of moderate and severe vision loss in uveitis patients.
- 03FDA has accepted the Biologics License Application with approval decision expected by July 2027.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Roche Holding AG54.09 USDMarket closedtoday +1.35%Positive Roche Holding AG366.60 CHFMarket closedtoday +1.55%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets